

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - Market Insights, Epidemiology, and Market Forecast 2028

<https://marketpublishers.com/r/RFE1C726650EN.html>

Date: August 2019

Pages: 120

Price: US\$ 6,250.00 (Single User License)

ID: RFE1C726650EN

Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's "Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - Market Insights, Epidemiology and Market Forecast – 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) epidemiology. It highlights the existing treatment patterns, potential upcoming Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.

Markets Covered

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2017-2028

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Understanding and Treatment Algorithm

The Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) market report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in the US, Europe, and Japan are also provided in the report.

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Epidemiology

This section provide the insights about historical and current Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Product Profiles & Analysis

This part of the report encloses the detailed analysis of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market Outlook

The Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight. Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Report Insights

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patient Population

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Therapeutic Approaches

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Pipeline Analysis

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market Size and Trends

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market Opportunities

Impact of upcoming Therapies in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Report Key Strengths

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) 10 Year Forecast

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) 7MM Coverage

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Epidemiology Segmentation

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Drugs Uptake

Highly Analyzed Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Market

Key Cross Competition

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Report Assessment

Current Treatment Practices in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Unmet Needs

Detailed Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Pipeline Product Profiles

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market Attractiveness

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market Drivers and Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) market

Organize sales and marketing efforts by identifying the best opportunities for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) market

To understand the future market competition in the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) market.

Contents

1. REPORT INTRODUCTION

2. RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) MARKET OVERVIEW AT A GLANCE

2.1. Market Share Distribution of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in 2017

2.2. Market Share Distribution of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in 2028

3. DISEASE BACKGROUND AND OVERVIEW: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in 7MM

4.3. Total Prevalent Patient Population of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in 7MM – By Countries

5. EPIDEMIOLOGY OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) BY COUNTRIES

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.1.3. Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia

(R/R AML) *Indication Specific

5.1.4. Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *Indication Specific

5.1.5. Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.1.6. Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.2. EU5

5.3. Assumptions and Rationale

5.4. Germany

5.4.1. Assumptions and Rationale

5.4.2. Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.4.3. Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.4.4. Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.4.5. Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.4.6. Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.5. France

5.5.1. Assumptions and Rationale

5.5.2. Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.5.3. Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.5.4. Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.5.5. Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.5.6. Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.6. Italy

5.6.1. Assumptions and Rationale

5.6.2. Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.6.3. Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.6.4. Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.6.5. Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.6.6. Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.7. Spain

5.7.1. Assumptions and Rationale

5.7.2. Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.7.3. Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.7.4. Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.7.5. Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.7.6. Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.8. United Kingdom

5.8.1. Assumptions and Rationale

5.8.2. Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.8.3. Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.8.4. Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.8.5. Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.8.6. Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.9. Japan

5.9.1. Assumptions and Rationale

5.9.2. Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

5.9.3. Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.9.4. Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) *

5.9.5. Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R

AML)

5.9.6. Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

6. CURRENT TREATMENT & MEDICAL PRACTICES

6.1. Treatment Algorithm

6.2. Treatment Guidelines

7. UNMET NEEDS OF THE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

8. MARKETED THERAPIES

8.1. Drug A: Company

8.1.1. Drug Description

8.1.2. Mechanism of Action

8.1.3. Regulatory Milestones

8.1.4. Advantages & Disadvantages

8.1.5. Product Profile

8.2. Drug B: Company

8.2.1. Drug Description

8.2.2. Mechanism of Action

8.2.3. Regulatory Milestones

8.2.4. Advantages & Disadvantages

8.2.5. Product Profile

9. PIPELINE THERAPIES – AT A GLANCE

10. KEY CROSS COMPETITION

11. EMERGING THERAPIES FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

11.1. Drug C: Company

11.1.1. Drug Description

11.1.2. Clinical Trials Details

11.1.3. Safety and Efficacy Profile

11.1.4. Advantages & Disadvantages

- 11.1.5. Pipeline Development Activities
- 11.1.6. Product Profile
- 11.2. Drug D: Company
 - 11.2.1. Drug Description
 - 11.2.2. Clinical Trials Details
 - 11.2.3. Safety and Efficacy Profile
 - 11.2.4. Advantages & Disadvantages
 - 11.2.5. Pipeline Development Activities
 - 11.2.6. Product Profile

12. RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) : 7MM MARKET ANALYSIS

- 12.1. 7MM Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- 12.2. 7MM Percentage Share of drugs marketed for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- 12.3. 7MM Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Products

13. RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) : COUNTRY-WISE MARKET ANALYSIS

- 13.1. United States
 - 13.1.1. Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States
 - 13.1.2. Percentage Share of drugs marketed for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States
 - 13.1.3. Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Products in United States
 - 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2. EU-5
 - 13.2.1. Germany
 - 13.2.1.1. Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany
 - 13.2.1.2. Percentage Share of drugs marketed for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany
 - 13.2.1.3. Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Products in Germany
 - 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.2. France

13.2.2.1. Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France

13.2.2.2. Percentage Share of drugs marketed for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France

13.2.2.3. Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Products in France

13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.3. Italy

13.2.3.1. Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Italy

13.2.3.2. Percentage Share of drugs marketed for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Italy

13.2.3.3. Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Products in Italy

13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.4. Spain

13.2.4.1. Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain

13.2.4.2. Percentage Share of drugs marketed for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain

13.2.4.3. Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Products in Spain

13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.5. United Kingdom

13.2.5.1. Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United Kingdom

13.2.5.3. Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

13.3. Japan

13.3.1. Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan

13.3.2. Percentage Share of drugs marketed for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan

13.3.3. Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. MARKET DRIVERS

15. MARKET BARRIERS

16. APPENDIX

17. REPORT METHODOLOGY

17.1. Sources

18. DELVEINSIGHT CAPABILITIES

19. DISCLAIMER

20. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in 7MM

Table 2: Total Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States (2017-2028)

Table 4: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States (2017-2028)

Table 5: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States (2017-2028)

Table 6: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States (2017-2028)

Table 7: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany (2017-2028)

Table 10: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany (2017-2028)

Table 11: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany (2017-2028)

Table 12: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France (2017-2028)

Table 14: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France (2017-2028)

Table 15: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France (2017-2028)

Table 16: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France (2017-2028)

Table 17: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France (2017-2028)

Table 18: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia

(R/R AML) in Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Italy (2017-2028)

Table 20: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Italy (2017-2028)

Table 21: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Italy (2017-2028)

Table 22: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain (2017-2028)

Table 25: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain (2017-2028)

Table 26: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain (2017-2028)

Table 27: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in UK (2017-2028)

Table 29: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in UK (2017-2028)

Table 30: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in UK (2017-2028)

Table 31: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in UK (2017-2028)

Table 32: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan (2017-2028)

Table 35: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan (2017-2028)

Table 36: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan (2017-2028)

Table 37: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41: 7MM- Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Table 42: 7MM- Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 43: 7MM- Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Table 45: United States-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Table 48: Germany-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Table 51: France-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Table 54: Italy-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Table 57: Spain-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Table 60:UK-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Table 63: Japan-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

List Of Figures

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States (2017-2028)

Figure 6: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States (2017-2028)

Figure 7: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany (2017-2028)

Figure 12: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France (2017-2028)

Figure 15: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France (2017-2028)

Figure 16: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France (2017-2028)

Figure 17: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid

Leukemia (R/R AML) in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid

Leukemia (R/R AML) in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia

(R/R AML) in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Italy (2017-2028)

Figure 22: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain (2017-2028)

Figure 27: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in UK (2017-2028)

Figure 31: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in UK (2017-2028)

Figure 32: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan (2017-2028)

Figure 37: Treatable Cases of the Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Figure 42:7MM- Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Figure 45: United States-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Figure 48: Germany-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Figure 51: France-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Figure 54: Italy-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Figure 57: Spain-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Figure 60:UK-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in USD MM (2017-2028)

Figure 63: Japan-Market Share Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) by Therapies in USD MM (2017-2028)

I would like to order

Product name: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - Market Insights, Epidemiology, and Market Forecast 2028

Product link: <https://marketpublishers.com/r/RFE1C726650EN.html>

Price: US\$ 6,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RFE1C726650EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

